-
1
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C
-
Ghany, M.G.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49, 1335–1374.
-
(2009)
An Update. Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
2
-
-
0036828784
-
The burden of hepatitis C in United States
-
Kim, W.R. The burden of hepatitis C in United States. Hepatology 2002, 36, S30–S34.
-
(2002)
Hepatology
, vol.36
, pp. S30-S34
-
-
Kim, W.R.1
-
3
-
-
77958105927
-
New antiviral therapies for chronic hepatitis C. Hepatol
-
Kanda T.; Imazeki, F.; Yokosuka, O. New antiviral therapies for chronic hepatitis C. Hepatol. Int. 2010, 4, 548–561.
-
(2010)
Int
, vol.4
, pp. 548-561
-
-
Kanda, T.1
Imazeki, F.2
Yokosuka, O.3
-
4
-
-
84892529894
-
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
-
European Association for Study of Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J. Hepatol. 2014, 60, 392–420.
-
(2014)
J. Hepatol
, vol.60
, pp. 392-420
-
-
-
5
-
-
84884257232
-
Treatment of hepatitis C virus infection in the future
-
Kanda T.; Yokosuka, O.; Omata, M. Treatment of hepatitis C virus infection in the future. Clin. Transl. Med. 2013, 2, 9.
-
(2013)
Clin. Transl. Med
, vol.2
, pp. 9
-
-
Kanda, T.1
Yokosuka, O.2
Omata, M.3
-
6
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison, J.G.; Everson, G.T.; Gordon, S.C.; Jacobson, I.M.; Sulkowski, M.; Kauffman, R.; McNair, L.; Alam, J.; Muir, A.J. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360, 1827–1838.
-
(2009)
N. Engl. J. Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
Jacobson, I.M.4
Sulkowski, M.5
Kauffman, R.6
McNair, L.7
Alam, J.8
Muir, A.J.9
-
7
-
-
65449171953
-
PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hezode, C.; Forestier, N.; Dusheiko, G.; Ferenci, P.; Pol, S.; Goeser, T.; Bronowicki, J.P.; Bourliere, M.; Gharakhanian, S.; Bengtsson, L., et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 2, 1839–1850.
-
(2009)
N. Engl. J. Med
, vol.2
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
Ferenci, P.4
Pol, S.5
Goeser, T.6
Bronowicki, J.P.7
Bourliere, M.8
Gharakhanian, S.9
Bengtsson, L.10
-
8
-
-
77950817619
-
PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection
-
McHutchison, J.G.; Manns, M.P.; Muir, A.J.; Terrault, N.A.; Jacobson, I.M.; Afdhal, N.H.; Heathcote, E.J.; Zeuzem, S.; Reesink, H.W.; Garg, J., et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010, 2, 1292–1303.
-
(2010)
N. Engl. J. Med
, vol.2
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
Terrault, N.A.4
Jacobson, I.M.5
Afdhal, N.H.6
Heathcote, E.J.7
Zeuzem, S.8
Reesink, H.W.9
Garg, J.10
-
9
-
-
79959438789
-
Telaprevir for previously untreated chronic HCV infection
-
Jacobson, I.M.; McHutchison, J.G.; Dusheiko, G.; di Bisceglie, A.M.; Reddy, K.R.; Bzowej, N.H.; Marcellin, P.; Muir, A.J.; Flisiak, R.; George, J., et al. Telaprevir for previously untreated chronic HCV infection. N. Engl. J. Med. 2011, 2, 2405–2416.
-
(2011)
N. Engl. J. Med
, vol.2
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
Marcellin, P.7
Muir, A.J.8
Flisiak, R.9
George, J.10
-
10
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S.; Focaccia, R.; Younossi, Z.; Foster, G.R.; Horban, A., et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011, 2, 2417–2428.
-
(2011)
N. Engl. J. Med
, vol.2
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.4
Diago, M.5
Roberts, S.6
Focaccia, R.7
Younossi, Z.8
Foster, G.R.9
Horban, A.10
-
11
-
-
80052826527
-
Response-guided teraprevir combination treatment for hepatitis C virus infection
-
Sherman, K.E.; Flamm, S.L.; Afdhal, N.H.; Nelson, D.R.; Sulkowski, M.S.; Everson, G.T.; Fried, M.W.; Adler, M.; Reesink, H.W.; Martin, M., et al. Response-guided teraprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011, 2, 1014–1024.
-
(2011)
N. Engl. J. Med
, vol.2
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
Nelson, D.R.4
Sulkowski, M.S.5
Everson, G.T.6
Fried, M.W.7
Adler, M.8
Reesink, H.W.9
Martin, M.10
-
12
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad, F.; McCone, J., Jr.; Bacon, B.R.; Bruno, S.; Manns, M.P.; Sulkowski, M.S.; Jacobson, I.M.; Reddy, K.R.; Goodman, Z.D.; Boparai, N., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 2, 1195–1206.
-
(2011)
N. Engl. J. Med
, vol.2
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
Jacobson, I.M.7
Reddy, K.R.8
Goodman, Z.D.9
Boparai, N.10
-
13
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
Bacon, B.R.; Gordon, S.C.; Lawitz, E.; Marcellin, P.; Vierling, J.M.; Zeuzem, S.; Poordad, F.; Goodman, Z.D.; Sings, H.L.; Boparai, N., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 2, 1207–1217.
-
(2011)
N. Engl. J. Med
, vol.2
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
Poordad, F.7
Goodman, Z.D.8
Sings, H.L.9
Boparai, N.10
-
14
-
-
84925879207
-
-
Available online, accessed on 1 March 2014
-
U.S. Food and Drug Administration. Available online: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm376449.htm(accessed on 1 March 2014).
-
-
-
-
15
-
-
84925867662
-
-
Available online: (accessed on 1 March 2014)
-
U.S. Food and Drug Administration. Available online: http://www.fda.gov/forconsumers/byaudience/ forpatientadvocates/ucm377920.htm (accessed on 1 March 2014).
-
-
-
-
16
-
-
84890945680
-
Virus protease inhibitor-resistance mutations: Our experience and review
-
Wu, S.; Kanda T.; Nakamoto, S.; Imazeki, F.; Yokosuka, O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J. Gastroenterol. 2013, 19, 8940–8948.
-
(2013)
World J. Gastroenterol
, vol.19
, pp. 8940-8948
-
-
Wu, S.1
Kanda, T.2
Nakamoto, S.3
Imazeki, F.4
Yokosuka, O.5
Hepatitis, C.6
-
17
-
-
0033429914
-
Molecular virology of the hepatitis C virus
-
De Francesco, R. Molecular virology of the hepatitis C virus. J. Hepatol. 1999, 31, 47–53.
-
(1999)
J. Hepatol
, vol.31
, pp. 47-53
-
-
De Francesco, R.1
-
18
-
-
84905961801
-
The elusive function of the hepatitis C virus p7 protein
-
Atoom, A.M.; Taylor, N.G.; Russell, R.S. The elusive function of the hepatitis C virus p7 protein. Virology 2014, 462, 377–387.
-
(2014)
Virology
, vol.462
, pp. 377-387
-
-
Atoom, A.M.1
Taylor, N.G.2
Russell, R.S.3
-
19
-
-
79961213651
-
Progress toward development of a hepatitis C vaccine with broad shoulders
-
Ray, R. Progress toward development of a hepatitis C vaccine with broad shoulders. Sci. Transl. Med. 2011, 3, doi:10.1126/scitranslmed.3002772.
-
(2011)
Sci.Transl. Med
, pp. 3
-
-
Ray, R.1
-
20
-
-
84901501952
-
Treatment with direct-acting antiviral agents for chronic hepatitis C virus infection
-
Kanda T.; Nakamoto, S.; Nakamura, M.; Jiang, X.; Miyamura, T.; Wu, S.; Yokosuka, O. Treatment with direct-acting antiviral agents for chronic hepatitis C virus infection. J. Clin. Transl. Hepatol. 2014, 2, 1–6.
-
(2014)
J. Clin. Transl. Hepatol
, vol.2
, pp. 1-6
-
-
Kanda, T.1
Nakamoto, S.2
Nakamura, M.3
Jiang, X.4
Miyamura, T.5
Wu, S.6
Yokosuka, O.7
-
21
-
-
78049316315
-
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A
-
White, P.W.; Llinàs-Brunet, M.; Amad, M.; Bethell, R.C., Bolger, G.; Cordingley, M.G.; Duan, J.; Garneau, M.; Lagacé, L.; Thibeault, D., et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 2010, 54, 4611–4618.
-
(2010)
Protease. Antimicrob. Agents Chemother
, vol.54
, pp. 4611-4618
-
-
White, P.W.1
Llinàs-Brunet, M.2
Amad, M.3
Bethell, R.C.4
Bolger, G.5
Cordingley, M.G.6
Duan, J.7
Garneau, M.8
Lagacé, L.9
Thibeault, D.10
-
22
-
-
0344201903
-
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
-
Lamarre, D.; Anderson, P.C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D.R.; Cartier, M.; Cordingley, M.G., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426, 186–189.
-
(2003)
Nature
, vol.426
, pp. 186-189
-
-
Lamarre, D.1
Anderson, P.C.2
Bailey, M.3
Beaulieu, P.4
Bolger, G.5
Bonneau, P.6
Bös, M.7
Cameron, D.R.8
Cartier, M.9
Cordingley, M.G.10
-
23
-
-
34848881891
-
Ultra-rapid cardiotoxicity of hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
-
Vanwolleghem, T.; Meuleman, P.; Libbrecht, L.; Roskams, T.; de Vos, R.; Leroux-Roels, G. Ultra-rapid cardiotoxicity of hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 2007, 133, 1144–1155.
-
(2007)
Gastroenterology
, vol.133
, pp. 1144-1155
-
-
Vanwolleghem, T.1
Meuleman, P.2
Libbrecht, L.3
Roskams, T.4
De Vos, R.5
Leroux-Roels, G.6
-
24
-
-
79953224799
-
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
-
Manns, M.P.; Bourliere, M.; Benhamou, Y.; Pol, S.; Bonacini, M.; Trepo, C.; Wright, D.; Berg, T.; Calleja, J.L.; White, P.W., et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol. 2011, 54, 1114–1122.
-
(2011)
J. Hepatol
, vol.54
, pp. 1114-1122
-
-
Manns, M.P.1
Bourliere, M.2
Benhamou, Y.3
Pol, S.4
Bonacini, M.5
Trepo, C.6
Wright, D.7
Berg, T.8
Calleja, J.L.9
White, P.W.10
-
25
-
-
84878992253
-
Faldaprevir combined with pegylated interferon α-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 Trial
-
Sulkowski, M.S.; Asselah, T.; Lalezari, J.; Ferenci, P.; Fainboim, H.; Leggett, B.; Bessone, F.; Mauss, S.; Heo, J.; Datsenko, Y., et al. Faldaprevir combined with pegylated interferon α-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 Trial. Hepatology 2013, 57, 2143–2154.
-
(2013)
Hepatology
, vol.57
, pp. 2143-2154
-
-
Sulkowski, M.S.1
Asselah, T.2
Lalezari, J.3
Ferenci, P.4
Fainboim, H.5
Leggett, B.6
Bessone, F.7
Mauss, S.8
Heo, J.9
Datsenko, Y.10
-
26
-
-
84878980518
-
Faldaprevir combined with peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 Trial
-
Sulkowski, M.S.; Bourliere, M.; Bronowicki, J.P.; Asselah, T.; Pawlotsky, J.M.; Shafran, S.D.; Pol, S.; Mauss, S.; Larrey, D.; Datsenko, Y., et al. Faldaprevir combined with peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 Trial. Hepatology 2013, 57, 2155–2163.
-
(2013)
Hepatology
, vol.57
, pp. 2155-2163
-
-
Sulkowski, M.S.1
Bourliere, M.2
Bronowicki, J.P.3
Asselah, T.4
Pawlotsky, J.M.5
Shafran, S.D.6
Pol, S.7
Mauss, S.8
Larrey, D.9
Datsenko, Y.10
-
27
-
-
84890126935
-
Safety and efficacy of faldaprevir with pegylated interferon α-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
-
Nishiguchi, S.; Sakai, Y.; Kuboki, M.; Tsunematsu, S.; Urano, Y.; Sakamoto, W.; Tsuda, Y.; Steinmann, G.; Omata, M. Safety and efficacy of faldaprevir with pegylated interferon α-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Liver Int. 2013, 34, 78–88.
-
(2013)
Liver Int
, vol.34
, pp. 78-88
-
-
Nishiguchi, S.1
Sakai, Y.2
Kuboki, M.3
Tsunematsu, S.4
Urano, Y.5
Sakamoto, W.6
Tsuda, Y.7
Steinmann, G.8
Omata, M.9
-
28
-
-
81855228070
-
Efficacy of the protease inhibitor BI 20135, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
-
Zeuzem, S.; Asselah, T.; Angus, P.; Zarski, J.P.; Larrey, D.; Müllhaupt, B.; Gane, E.; Schuchmann, M.; Lohse, A.; Pol, S., et al. Efficacy of the protease inhibitor BI 20135, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011, 141, 2047–2055.
-
(2011)
Gastroenterology
, vol.141
, pp. 2047-2055
-
-
Zeuzem, S.1
Asselah, T.2
Angus, P.3
Zarski, J.P.4
Larrey, D.5
Müllhaupt, B.6
Gane, E.7
Schuchmann, M.8
Lohse, A.9
Pol, S.10
-
29
-
-
84881405876
-
Faldaprevir and deleobuvir for HCV genotype 1 infection
-
Zeuzem, S.; Soriano, V.; Asselah, T.; Bronowicki, J.P.; Lohse, A.W.; Müllhaupt, B.; Schuchmann, M.; Bourlière, M.; Buti, M.; Roberts, S.K, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 2013, 369, 630–639.
-
(2013)
N. Engl. J. Med
, vol.369
, pp. 630-639
-
-
Zeuzem, S.1
Soriano, V.2
Asselah, T.3
Bronowicki, J.P.4
Lohse, A.W.5
Müllhaupt, B.6
Schuchmann, M.7
Bourlière, M.8
Buti, M.9
Roberts, S.K.10
-
30
-
-
84455161773
-
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob
-
Lagace, L.; White, P.W.; Bousquet, C.; Dansereau, N.; Dô, F.; Llinas-Brunet, M.; Marquis, M.; Massariol, M.J.; Maurice, R.; Spickler, C., et al. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob. Agents Chemother. 2012, 56, 569–572.
-
(2012)
Agents Chemother
, vol.56
, pp. 569-572
-
-
Lagace, L.1
White, P.W.2
Bousquet, C.3
Dansereau, N.4
Dô, F.5
Llinas-Brunet, M.6
Marquis, M.7
Massariol, M.J.8
Maurice, R.9
Spickler, C.10
-
31
-
-
84924353003
-
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation
-
Sabo, J.P.; Kort, J.; Ballow, C.; Kashuba, A.D.; Haschke, M.; Battegay, M.; Girlich, B.; Ting, N.; Lang, B.; Zhang, W., et al. Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation. J. Clin. Pharmacol. 2015, doi: 10.1002/jcph.436.
-
(2015)
J. Clin. Pharmacol
-
-
Sabo, J.P.1
Kort, J.2
Ballow, C.3
Kashuba, A.D.4
Haschke, M.5
Battegay, M.6
Girlich, B.7
Ting, N.8
Lang, B.9
Zhang, W.10
-
32
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
-
Ghany, M.G.; Nelson, D.R.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54, 1433–1444.
-
(2011)
Hepatology
, vol.54
, pp. 1433-1444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
Thomas, D.L.4
Seeff, L.B.5
-
33
-
-
84862850805
-
APASL consensus statements and management algorithms for hepatitis C virus infection
-
Omata, M.; Kanda T.; Yu, M.L.; Yokosuka O.; Lim, S.G.; Jafri, W.; Tateishi, R.; Hamid, S.S.; Chuang, W.L.; Chutaputti, A., et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol. Int. 2012, 6, 409–435.
-
(2012)
Hepatol. Int
, vol.6
, pp. 409-435
-
-
Omata, M.1
Kanda, T.2
Yu, M.L.3
Yokosuka, O.4
Lim, S.G.5
Jafri, W.6
Tateishi, R.7
Hamid, S.S.8
Chuang, W.L.9
Chutaputti, A.10
-
34
-
-
84924065501
-
Role of IL28B genotype in older hepatitis C virus-infected patients. World
-
Kanda T.; Nakamoto, S.; Wu, S.; Yokosuka, O. Role of IL28B genotype in older hepatitis C virus-infected patients. World J. Immunol. 2013, 3, 54–61.
-
(2013)
J. Immunol
, vol.3
, pp. 54-61
-
-
Kanda, T.1
Nakamoto, S.2
Wu, S.3
Yokosuka, O.4
-
35
-
-
84925873726
-
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
-
Ferenci, P.; Asselah, T.; Foster, G.R.; Zeuzem, S.; Sarrazin, C.; Moreno, C.; Ouzan, D.; Maevskaya, M.; Calinas, F.; Morano, L.E., et al. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. J. Hepatol. 2015, doi:10.1016/j.jhep.2014.12.024.
-
(2015)
J. Hepatol
-
-
Ferenci, P.1
Asselah, T.2
Foster, G.R.3
Zeuzem, S.4
Sarrazin, C.5
Moreno, C.6
Ouzan, D.7
Maevskaya, M.8
Calinas, F.9
Morano, L.E.10
-
36
-
-
84931568272
-
HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b
-
in press
-
Hirotsu, Y.; Kanda T.; Matsumura, H.; Moriyama, M.; Yokosuka, O.; Omata, M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol. Int. 2015, in press.
-
(2015)
Hepatol. Int
-
-
Hirotsu, Y.1
Kanda, T.2
Tsumur, H.3
Oriyam, M.4
Yokosuk, O.5
Omata, M.6
-
37
-
-
42949167169
-
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob
-
McCown, M.F.; Rajyaguru, S.; le Pogam, S.; Ali, S.; Jiang, W.R.; Kang, H.; Symons, J.,Cammack, N.; Najera, I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52, 1604–1612.
-
(2008)
Agents Chemother
, vol.52
, pp. 1604-1612
-
-
McCown, M.F.1
Rajyaguru, S.2
Le Pogam, S.3
Ali, S.4
Jiang, W.R.5
Kang, H.6
Symons, J.7
Cammack, N.8
Najera, I.9
-
38
-
-
84888210472
-
Antiviral therapy for “difficult-to-treat” hepatitis C virus-infected patients
-
Kanda T.; Yokosuka, O.; Omata, M. Antiviral therapy for “difficult-to-treat” hepatitis C virus-infected patients. Chin. Med. J. 2013, 126, 4568–4574.
-
(2013)
Chin. Med. J
, vol.126
, pp. 4568-4574
-
-
Kanda, T.1
Yokosuka, O.2
Omata, M.3
-
39
-
-
84921453842
-
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study
-
Zeuzem, S.; Dufour, J.F.; Buti, M.; Soriano, V.; Buynak, R.J.; Mantry, P.; Taunk, J.; Stern, J.O.; Vinisko, R.; Gallivan, J.P., et al. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver Int. 2015, 35, 417–421.
-
(2015)
Liver Int
, vol.35
, pp. 417-421
-
-
Zeuzem, S.1
Dufour, J.F.2
Buti, M.3
Soriano, V.4
Buynak, R.J.5
Mantry, P.6
Taunk, J.7
Stern, J.O.8
Vinisko, R.9
Gallivan, J.P.10
-
40
-
-
84921909959
-
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis
-
Zeuzem, S.; Soriano, V.; Asselah, T.; Gane, E.J.; Bronowicki, J.P.; Angus, P.; Lohse, A.W.; Stickel, F.; Müllhaupt, B.; Roberts, S., et al. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Antimicrob. Agents Chemother. 2015, 59, 1282–1291.
-
(2015)
Antimicrob. Agents Chemother
, vol.59
, pp. 1282-1291
-
-
Zeuzem, S.1
Soriano, V.2
Asselah, T.3
Gane, E.J.4
Bronowicki, J.P.5
Angus, P.6
Lohse, A.W.7
Stickel, F.8
Müllhaupt, B.9
Roberts, S.10
|